本文選題：蒲元和胃 + 序貫療法　； 參考：《山東中醫(yī)藥大學(xué)》2014年碩士論文

【摘要】：目的：通過對蒲元和胃膠囊聯(lián)合PPI與抗生素采用序貫療法治療Hp相關(guān)性胃�。ㄖ饕晕秆着c消化性潰瘍）的臨床觀察，分析其療效與適應(yīng)癥，，為采用此方案個體化治療Hp相關(guān)性胃病提供資料。 方法：300例Hp陽性慢性胃炎與消化性潰瘍患者，按隨機原則分為兩組，治療組采用蒲元和胃膠囊聯(lián)合PPI和抗生素行序貫治療，對照組采用西藥三聯(lián)療法。觀察記錄兩組患者總療效情況、胃鏡療效、各病種療效、中醫(yī)證型療效、Hp根除率、不良反應(yīng)發(fā)生等情況。 結(jié)果：280例完成治療與復(fù)查。治療組與對照組總有效率分別為96.6%和85.9%，總顯效率分別為88.3%和69.6%，差異有統(tǒng)計學(xué)意義(P0.05)。胃鏡療效方面兩組有效率為97.9%和96.3%，顯效率為89.7%和86.7%，差異無統(tǒng)計學(xué)意義(P0.05)。Hp根除率方面兩組分別為92.4%和93.3%，差異無統(tǒng)計學(xué)意義(P0.05)。各病種療效方面，慢性淺表性胃炎的治療上兩組有效率與顯效率差異無統(tǒng)計學(xué)意義(P0.05)，慢性萎縮性胃炎、胃和十二指腸潰瘍的治療上有效率與顯效率差異有統(tǒng)計學(xué)意義(P0.05)。在中醫(yī)證型療效方面，兩組在中醫(yī)9個分型中的6個證型的有效率與顯效率上差異有統(tǒng)計學(xué)意義(P0.05)。治療組的不良反應(yīng)少于對照組。 結(jié)論：本方案在達(dá)到較高Hp根除率的基礎(chǔ)上療效更好、不良反應(yīng)少，較適合在中醫(yī)辨證的基礎(chǔ)上對Hp相關(guān)性胃病進(jìn)行個體化治療。
[Abstract]:Objective: to observe the clinical effects and indications of PPI combined with PPI and antibiotics in the treatment of HP associated gastropathy (including chronic gastritis and peptic ulcer). To provide data for individualized treatment of HP-associated gastropathy. Methods 300 patients with HP positive chronic gastritis and peptic ulcer were randomly divided into two groups. The treatment group was treated with Puyuanghe capsule combined with PPI and antibiotics, and the control group was treated with western medicine triple therapy. To observe and record the total curative effect of the two groups, the curative effect of gastroscope, the curative effect of each disease, the curative effect of TCM syndrome type and the eradication rate of HP, the occurrence of adverse reaction and so on. Results the treatment and reexamination were completed in 280 cases. The total effective rates of the treatment group and the control group were 96.6% and 85.9%, respectively. The total effective rate was 88.3% and 69.6%, respectively. The difference was statistically significant (P0.05). The effective rate of gastroscopy was 97.9% and 96.3%, the effective rate was 89.7% and 86.7%, the difference was not statistically significant (P0.05). The eradication rate of HP in the two groups was 92.4% and 93.3%, respectively (P0.05). There was no significant difference between the two groups (P0.05). In the treatment of chronic superficial gastritis, there was no significant difference in the effective rate and the effective rate between the two groups (P0.05), while the effective rate and the effective rate in the treatment of chronic atrophic gastritis, gastric and duodenal ulcer were statistically significant (P0.05). In TCM syndromes, the effective rate and effective rate of 6 syndromes in 9 types of TCM were significantly different between the two groups (P0.05). The adverse reactions in the treatment group were less than those in the control group. Conclusion: this scheme has better curative effect and fewer adverse reactions on the basis of higher eradication rate of HP. It is more suitable for individualized treatment of HP related gastropathy on the basis of TCM syndrome differentiation.
【學(xué)位授予單位】：山東中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R573

【參考文獻(xiàn)】

相關(guān)期刊論文 前7條

1 張謙;楊文奇;;2型糖尿病患者幽門螺旋桿菌感染及其臨床意義[J];長春中醫(yī)藥大學(xué)學(xué)報;2007年03期

2 姜成,鄢春錦,劉蔚雯,張學(xué)敏;15味中藥抑制幽門螺桿菌的體外實驗[J];福建中醫(yī)學(xué)院學(xué)報;2003年06期

3 施光亞;林瑜;陳朝元;;三黃片治療幽門螺桿菌感染性慢性胃炎的療效觀察[J];福建中醫(yī)學(xué)院學(xué)報;2007年06期

4 姚慧靜;;蒲元和胃膠囊聯(lián)合多潘立酮治療功能性消化不良的療效觀察[J];臨床合理用藥雜志;2012年15期

5 李磊;魏瑋;王常會;;蒲元和胃膠囊對內(nèi)毒素血癥大鼠急性胃粘膜病變的保護(hù)作用[J];齊魯藥事;2010年11期

6 劉希雙,劉成娟,孟淑芬,劉吉華,唐立民,孫義堂;蒲元胃康膠囊治療慢性胃炎和消化性潰瘍的效果[J];齊魯醫(yī)學(xué)雜志;1999年03期

7 陳萍;張利;;蒲元和胃膠囊治療慢性非萎縮性胃炎療效觀察[J];社區(qū)醫(yī)學(xué)雜志;2012年08期

本文編號：2096670